VIDEO: Combination active in subset of women with triple-negative breast cancer
SAN ANTONIO — The combination of mifepristone and eribulin appeared active in women with recurrent, glucocorticoid receptor–positive triple-negative breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.
Sharon Wilks, MD, FACP — medical oncologist with Texas Oncology, a practice in The US Oncology Network — and colleagues also found the combination to be well tolerated.
“It’s really important to know when you’re struggling with a patient who has had recurrent disease that ... you can find targets that may actually be very effective,” Wilks said. – by Kristie L. Kahl
Disclosure: Wilks reports no relevant financial disclosures.